



OPEN ACCESS

EDITED AND REVIEWED BY
Shiv K. Gupta,
Mayo Clinic, United States

*CORRESPONDENCE
Wenchu Lin
✉ wenchu@hmf.ac.cn

SPECIALTY SECTION
This article was submitted to
Cancer Molecular Targets
and Therapeutics,
a section of the journal
Frontiers in Oncology

RECEIVED 23 March 2023
ACCEPTED 27 March 2023
PUBLISHED 12 April 2023

CITATION
Bian X, Wang X, Zhang Q, Ma L, Cao G,
Xu A, Han J, Huang J and Lin W (2023)
Corrigendum: The MYC paralog-PARP1
axis as a potential therapeutic
target in MYC paralog-activated
small cell lung cancer.
Front. Oncol. 13:1192526.
doi: 10.3389/fonc.2023.1192526

COPYRIGHT
© 2023 Bian, Wang, Zhang, Ma, Cao, Xu,
Han, Huang and Lin. This is an open-access
article distributed under the terms of the
Creative Commons Attribution License
(CC BY). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that
the original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Corrigendum: The MYC paralog-PARP1 axis as a potential therapeutic target in MYC paralog-activated small cell lung cancer

Xing Bian^{1,2,3,4}, Xiaolin Wang^{1,2,3,4}, Qiuyan Zhang⁵, Liying Ma^{1,2,3,4}, Guozhen Cao^{1,2,3,4}, Ao Xu^{6,7}, Jinhua Han⁸, Jun Huang⁸ and Wenchu Lin^{1,3,4*}

¹High Magnetic Field Laboratory, Chinese Academy of Sciences, Hefei, China, ²University of Science and Technology of China, Hefei, China, ³Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, China, ⁴High Magnetic Field Laboratory of Anhui Province, Hefei, China, ⁵The CAS Key Laboratory of Innate Immunity and Chronic Disease, Innovation Center for Cell Signaling Network, School of Life Sciences, University of Science and Technology of China, Hefei, China, ⁶The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China, ⁷Department of Pathology, Anhui Provincial Hospital, Hefei, China, ⁸MOE Key Laboratory for Biosystems Homeostasis & Protection and Innovation Center for Cell Signaling Network, Life Sciences Institute, Zhejiang University, Hangzhou, China

KEYWORDS

small cell lung cancer, MYC paralog, PARP1, BET, DNA damage response

A corrigendum on

The MYC paralog-PARP1 axis as a potential therapeutic target in MYC paralog-activated small cell lung cancer

by Bian X, Wang X, Zhang Q, Ma L, Cao G, Xu A, Han J, Huang J and Lin W (2020) *Front. Oncol.* 10:565820. doi: 10.3389/fonc.2020.565820

Error in Figure/Table

In the published article, there was an error in [Figure 3E](#) as published. The representative picture of western blot bands of cleaved PARP1 of H446 cells were presented incorrectly. The corrected [Figure 3E](#) and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.




FIGURE 3

The combination effects of JQ1 and BMN673 in SCLC cells. (A–D) CellTiter-Glo Luminescent assays demonstrating the effects of JQ1 and BMN673 as single agents or in combination in MYC paralog-dependent (A), independent (B) SCLC cells, DMS53 cells with c-MYC knockdown (C), and SHP77 cells with c-MYC overexpression (D). A mathematical model was applied to calculate the combination index using the CalcuSyn software program. (E) Western blot analysis of cleaved PARP and MYC paralogs in SCLC cells treated with BMN673 or JQ1 alone or in combination for 24 h. c-MYC for H82, H446 and DMS273, MYCN for H526 and H69, MYCL for H1963. (F) Western blot analysis of cleaved PARP and c-MYC in SHP77 cells with c-MYC overexpression followed by BMN673 and JQ1 treatment alone or in combination for 24 h. GAPDH was used as a loading control. (G) Tumor sphere structures in 3D matrigel were captured under a phase-contrast microscope upon treatment of JQ1 and BMN673 as single agents or in combination for 10 to 15 days. Representative images of tumor spheres were shown in the top panel. Quantification of scored tumor sphere structures (disintegrated, semi-disintegrated, and intact) was shown in the bottom panel. Scale bar, 40 μm. (H) 3D matrigel assays showing the effect of JQ1 and BMN673 in SHP77 cells with or without c-MYC overexpression. 1, Vehicle; 2, BMN673; 3, JQ1; 4, JQ1+BMN673.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.